Boston Sci acquires tech to treat CTOs

Boston Scientific has acquired two novel technologies to treat peripheral chronic total occlusions (CTOs), which normally can't be treated with standard endovascular devices such as guidewires and other catheter-based technologies. 

In a statement, Boston Scientific says it acquired a re-entry catheter from Israel's S.I. Therapies in November. And it will obtain an intraluminal CTO crossing device through its acquisition of Sunnyvale, CA-based ReVascular Therapeutics. This acquisition is expected to close this month. Worldwide launches of these devices in approved markets are planned later this year. 

Together, the transactions are expected to have an immaterial impact on GAAP and adjusted earnings this year and in 2012, and be accretive thereafter. Transactional financial terms were not disclosed. 

"Having used both devices, I am impressed with their simplicity and effectiveness," explains Dierk Scheinert, Heart Center Leipzig, and Professor of Medicine at the University of Leipzig. "Access to these technologies will greatly enhance therapeutic options and provide physicians with new, intuitive solutions for treating challenging CTOs," Scheinert adds.

"These acquisitions demonstrate our continued strategic execution of realigning and strengthening our portfolio in areas with high-growth potential," says Boston Scientific President and CEO Ray Elliott. "Our Priority Growth Initiatives include peripheral vascular disease, in which a significant number of patients remain undiagnosed or untreated. Addressing these challenges through use of less-invasive devices could greatly improve the care these patients receive." 

Boston Scientific shares were down 0.6 percent to $6.93 in after-hours trading, Dow Jones reports.

- check out the Boston Scientific release
- get more from Dow Jones

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.